KOSDAQBiotech & Pharma041910

Polaris AI Pharma

₩4,860▼ 2.31%2026-11-18 close
Market Cap
₩64.6B
Turnover
₩200M
Volume
40K
Shares out.
13.3M
PER
6.4×
PBR
0.5×
EPS
₩787
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Profit rebound meets a Q3 2026 net loss; core margins in focus

Polaris AI Pharma's 2025 operating profit rebounded sharply on a 2024 base, but in Q3 2026 operating profit fell to KRW 52.61 million and the company posted a controlling-shareholder net loss, making the durability of profit the key item to track.

  1. 1

    Operating profit for 2025 was KRW 3.19 billion, up 1,712.2% from the prior year, and controlling-shareholder net income rose 56.1% to KRW 6.16 billion.

  2. 2

    Revenue declined in both 2024 (down 7.2%) and 2025 (down 6.8%), falling to KRW 55.5 billion in 2025.

  3. 3

    Q3 2026 operating profit was KRW 52.61 million, down 96.7% year on year, and the company posted a controlling-shareholder net loss of KRW 333 million.

  4. 4

    The debt-to-equity ratio rose from 4.6% in 2024 to 44.1% in 2025, and KRW 10 billion of convertible bonds were issued in March 2026.

  5. 5

    API expansion continues, including a majority share of Japan's duloxetine API market as claimed by the company and Korean DMF registrations for lurasidone and duloxetine.

02

Business structure

Polaris AI Pharma is a pharmaceutical company centered on active pharmaceutical ingredients (APIs) and contract development and manufacturing (CDMO).

It runs a generic-based API and CDMO business on a stable basis, and since joining the Polaris group it has also widened its scope into an AI-based pharmaceutical R&D data business together with Polaris Office.

In February 2026 it signed a joint R&D MOU with a Korean drug developer covering API process optimization, GMP production of clinical samples and regulatory documentation support.

Its core product line is central nervous system (CNS) APIs, and the company said its duloxetine hydrochloride holds a majority share of the Japanese market.

The product was registered with Japan's MF in 2019 and has been supplied to major local pharmaceutical companies since a 2020 linked review of finished-dosage products.

Its in-house lurasidone hydrochloride completed a Korean DMF registration in August 2026, and a Korean DMF registration for duloxetine hydrochloride was announced on November 11, 2026. The company said it is preparing a Japanese MF filing for lurasidone hydrochloride.

Abroad, it completed an API registration with China's National Medical Products Administration (NMPA) for a gastric ulcer treatment and began commercial sales, and press reports in September 2025 cited government tender wins in Russia and Mexico and a new contract in Saudi Arabia.

Its investment arm holds stakes in biotech companies; press reports said it realized gains by selling shares of a KOSDAQ-listed investee around that company's December 2025 listing, while it still held shares in Nasdaq-listed Alpha Tau Medical as of February 2026.

In March 2026 the company signed an MOU with a drug distributor on domestic API supply, aimed at the cost pressure created by drug price cuts.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩14.7B₩1.6B10.7%
2025Q4₩14.3B-₩400M−2.7%
2026Q1₩13.7B₩600M4.4%
2026Q2₩14.7B₩800M5.3%
2026Q3₩11.9B₩52,612,7640.4%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩62B₩3.2B-₩6.4B5.1%−5.5%7.1%
2023₩64.2B₩5.3B₩3.8B8.3%3.3%5.4%
2024₩59.6B₩200M₩3.9B0.3%3.1%4.6%
2025₩55.5B₩3.2B₩6.2B5.7%4.5%44.1%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-18

04

Earnings analysis

On an annual basis, revenue rose from KRW 62 billion in 2022 to KRW 64.2 billion in 2023 (up 3.5% year on year), then fell to KRW 59.6 billion in 2024 (down 7.2%) and KRW 55.5 billion in 2025 (down 6.8%), declining for two consecutive years from 2024 through 2025. 2023 was the largest year and 2025 the smallest among 2022 to 2025.

Operating profit went from KRW 3.16 billion in 2022 to KRW 5.34 billion in 2023 (up 69.0%), fell to KRW 176 million in 2024 (down 96.7%, the smallest year), and recovered to KRW 3.19 billion in 2025 (up 1,712.2%).

The company attributed the 2025 recovery to a base effect after one-off costs in 2024, including retirement payments tied to the Polaris group acquisition, plus group-wide cuts in selling and administrative expenses. Operating margin moved from 5.1% in 2022 to 8.3% in 2023, 0.3% in 2024 and 5.7% in 2025.

Controlling-shareholder net income swung from a loss of KRW 6.36 billion in 2022 to income of KRW 3.82 billion in 2023, then rose to KRW 3.95 billion in 2024 and KRW 6.16 billion in 2025, increasing for two consecutive years from 2024 through 2025.

The company said the 2025 rise in net income was also helped by higher gains from disposal and valuation of investment stakes.

At the end of 2025, total equity was KRW 135.9 billion, all attributable to controlling shareholders, and total liabilities were KRW 60 billion, lifting the debt-to-equity ratio from 4.6% in 2024 to 44.1% in 2025.

Operating cash flow was negative KRW 1.65 billion in 2022 and rose to KRW 4.79 billion in 2023, KRW 7.93 billion in 2024 and KRW 8.83 billion in 2025.

Quarterly, operating profit of KRW 1.57 billion in Q3 2025 turned into an operating loss of KRW 392 million in Q4 2025, then returned to a profit of KRW 606 million in Q1 2026. Q2 2026 revenue was KRW 14.7 billion (up 7.3% quarter on quarter) and operating profit was KRW 779 million (up 28.4%).

Q3 2026 revenue fell to KRW 11.9 billion (down 18.8% quarter on quarter and year on year), operating profit fell to KRW 52.61 million (down 93.2% quarter on quarter and 96.7% year on year), and the company posted a controlling-shareholder net loss of KRW 333 million.

Controlling-shareholder net income over the last four quarters totaled KRW 10.4 billion, with the KRW 6.75 billion recorded in Q2 2026 making up most of it.

That Q2 2026 controlling-shareholder net income was far larger than the KRW 779 million operating profit indicates that non-operating gains weighed heavily on that quarter.

05

Industry analysis

The API market moves with the cost pressure on finished-dosage drugmakers. In its March 2026 MOU announcement, the company said cost management and a stable supply chain had become core survival strategies for finished-product makers under a drug-price-cut policy push.

According to press reports, the government is encouraging the use of domestic APIs in essential medicines for health-security reasons and aims to raise self-sufficiency.

The company was selected as lead organization of the Ministry of Health and Welfare's raw material procurement diversification support program, which covers API localization and process innovation.

According to the company's press release, the DMF registration of lurasidone made from a domestic plant is the first of its kind in Korea. Cycle position is best gauged through policy direction and product registration progress, and the company completed two Korean DMF registrations in 2026.

Against peers, listed companies focused on biologics manufacturing or biosimilars are centered on large-molecule production, while this company is centered on small-molecule synthetic APIs. Its reported majority share of Japan's duloxetine API market points to a strong supply position in one product.

Still, reliance on one market and one product can make revenue sensitive to customer adoption decisions. Its push into overseas government tenders fits a strategy of diversifying supply across countries and customers.

Drug price cuts that strengthen finished-product makers' bargaining power can also affect API pricing negotiations, which is a common variable across the industry.

06

Outlook

The business plans the company has disclosed center on domestic API localization and CDMO expansion.

On February 26, 2026 the company signed a joint R&D MOU with a Korean drug developer covering new drugs and improved new drugs, and said it would support API process optimization, GMP production of nonclinical and clinical samples, and regulatory document (CTD) preparation.

Its March 5, 2026 MOU with a drug distributor set out five core tasks, including cost-competitive API planning, supply systems for essential medicines and supply-sensitive items, and joint development of CNS-class APIs.

The company said a Japanese MF filing for lurasidone is in preparation, and that technical evaluation for adoption is under way with a local customer.

Its push into overseas government tenders was described in September 2025 press coverage, when a company official said cooperation with private pharmaceutical companies would be expanded alongside government procurement in 2026.

An AI solution for pharmaceuticals is being developed jointly with Polaris Office, using retrieval-augmented generation (RAG) technology to build a domain-specific AI model; it remains in development.

The KRW 10 billion convertible bond issued in March 2026 carries a 0.0% coupon and matures in 2030, and the company said proceeds will fund R&D for API localization and CDMO expansion among other uses.

The conversion period starts on March 26, 2027, and conversion would issue 1,098,177 common shares, equal to 7.52% of total shares.

On the investment side, Alpha Tau Medical announced in February 2026 that it received Japanese marketing approval for its head-and-neck cancer radiotherapy device, and press coverage said this could highlight the value of the company's stake. On March 23, 2026 Lee Seong-yeop was appointed a co-CEO alongside Cho Won-kyung, changing the management setup.

07

Valuation

PER
6.4×
PBR
0.5×
ROE
7.4%
EPS
₩787
BPS
₩11,108
Dividend per share
₩0

The price-to-book ratio is below 1x, which places the share price at a low level relative to book value per share. Total equity of KRW 135.9 billion at the end of 2025 is entirely attributable to controlling shareholders, and total liabilities were KRW 60 billion.

Earnings-based multiples are calculated on controlling-shareholder net income of KRW 10.4 billion over the last four quarters, and that total includes amounts from non-operating items, such as the KRW 6.75 billion recorded in Q2 2026.

On an operating-profit basis, Q3 2026 operating profit fell to KRW 52.61 million, which widens the range of interpretation for earnings-based multiples.

The dividend yield is effectively nil, and the share cancellation of 218,257 common shares approved by the board on March 19, 2026 served as the shareholder return measure. The March 2026 convertible bonds would add 1,098,177 new shares if converted, leaving share count changes as a factor.

Compared with sector peers, the key point is that interpretation of multiples depends on the quality of earnings.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-18

08

Bull factors

A turn toward profit recovery

Operating profit recovered to KRW 3.19 billion in 2025, and the operating margin rose from 0.3% in 2024 to 5.7%. The company cited the base effect of one-off costs in 2024 and cuts in selling and administrative expenses as the drivers.

Controlling-shareholder net income has grown since the swing from a 2022 loss to profit in 2023, which supports the case for a change in earnings structure.

Japanese share and Korean DMF registrations

The company said it holds a majority share of Japan's duloxetine API market. Korean DMF registrations for lurasidone hydrochloride in August 2026 and for duloxetine hydrochloride announced on November 11, 2026 add a basis for domestic supply. The company says this positions it for policy moves favoring domestic API localization under drug price cuts.

Possible highlighting of investment stakes

Alpha Tau Medical, an investee, announced in February 2026 that it received Japanese marketing approval for its head-and-neck cancer radiotherapy device. Press coverage said this could bring attention to the value of the company's stake.

Press reports said the company realized gains by selling shares of a KOSDAQ-listed investee around that company's listing.

09

Bear factors

Sharp Q3 profit drop and a return to loss

In Q3 2026, operating profit fell sharply from a year earlier, and the controlling-shareholder net result turned to a loss. Revenue also fell 18.8% year on year to KRW 11.9 billion. Compared with KRW 779 million of operating profit in Q2 2026, the quarterly profit trend weakened sharply.

Revenue down two years in a row

Revenue fell in both 2024 (down 7.2% to KRW 59.6 billion) and 2025 (down 6.8% to KRW 55.5 billion). According to the company, the 2025 profit recovery was driven by the base effect of one-off costs and lower selling and administrative expenses. Whether profit recovery holds while revenue shrinks was tested in Q3 2026.

Rising leverage and earnings quality

The debt-to-equity ratio rose from 4.6% in 2024 to 44.1% in 2025. The KRW 10 billion convertible bond issued in March 2026 carries a 0.0% coupon and matures in 2030, and conversion could issue 1,098,177 common shares, or 7.52% of total shares.

The company said the 2025 rise in net income also reflected higher gains from disposal and valuation of investment stakes.

10

Risk factors

Policy and drug pricing

If drug price cuts continue, cost pressure on finished-product makers could pass through to API supply price negotiations. The company promoted cost-competitive API planning through its MOU with a distributor, but the effect of policy changes on profitability has not yet appeared quantitatively in quarterly results. Whether domestic API localization policy turns into demand at the expected scale is also a variable.

Investment stakes and non-operating items

Net income attributable to controlling shareholders moves sharply with gains and losses on investment stakes. Q2 2026 controlling-shareholder net income of KRW 6.75 billion far exceeded operating profit of KRW 779 million, and Q3 2026 swung to a net loss of KRW 333 million. Price changes in listed investments also flow through earnings, reducing their stability.

Commercialization and management

The Japanese MF filing for lurasidone, the pharmaceutical AI solution and overseas government tenders have either no disclosed timetable or remain at the preparation stage. On March 23, 2026 Lee Seong-yeop was appointed a co-CEO, changing the management setup.

Because a large part of the strategy relies on collaboration within the group, changes in group strategy could affect the company.

11

What to watch next

  1. Late March 2027

    The 2026 annual report will show how annual revenue and operating margin compare with 5.7% in 2025, and how the Q3 2026 swing to a loss is reflected in the full-year figures. The operating margin in that regular report is the next checkpoint.

  2. March 26, 2027

    The conversion period for the March 2026 convertible bonds begins. The scale of conversion and whether call option provisions are exercised will determine the extent of share count changes.

  3. Mid-May 2027

    The Q1 2027 quarterly report will show whether operating profit recovers from the KRW 52.61 million of Q3 2026 and how core operating earnings move excluding non-operating items.

  4. From late 2026 (timing not fixed)

    Progress on the Japanese MF filing for lurasidone and the commercial rollout of Alpha Tau Medical in Japan, and their effect on investment valuations and API expansion.

12

Overall view

Polaris AI Pharma is a pharmaceutical company centered on APIs and CDMO, and its 2025 reported results show operating profit recovering to KRW 3.19 billion and a shift in its earnings structure.

Revenue, however, fell in both 2024 and 2025, and in Q3 2026 operating profit dropped to KRW 52.61 million and the company swung to a controlling-shareholder net loss.

On the overseas side, the company reports a majority share of Japan's duloxetine API market, two Korean DMF registrations, a China registration and government tender wins in Russia and Mexico, which together add to the API business.

On the investment side, Alpha Tau Medical's Japanese approval and gains realized on Quadmedison are variables affecting earnings, and the 2025 rise in net income also included these items.

Financially, the debt-to-equity ratio rose to 44.1%, and conversion of the bonds issued in March 2026 could increase the share count. On valuation, the price-to-book ratio sits below 1x, while earnings-based multiples vary with non-operating items and quarterly earnings volatility.

The next checkpoints are the annual operating margin in the 2026 annual report, the start of the conversion period on March 26, 2027, and whether operating profit recovers in Q1 2027.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. view.asiae.co.kr
  2. etoday.co.kr
  3. news.nate.com
  4. finance-scope.com
  5. pmstoryhub.com
  6. newsis.com
  7. medicopharma.co.kr
  8. hankyung.com
  9. etoday.co.kr
  10. newspim.com
  11. vegannews.co.kr
  12. fnnews.com
  13. news.nate.com
  14. view.asiae.co.kr
  15. m.news.nate.com
  16. m.news.nate.com
  17. topstarnews.net
  18. thebell.co.kr

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis